CanaQuest MEDICAL CORP

Corporate Presentation

Q2 2022

Mission

| To advance cannabinoid & botanical-based medicine to the forefront by deploying best-practice science, clinical trials, and emerging technologies

CanaQuest MEDICAL CORP

Forward Looking Statements

To the extent of statements made in this presentation contains forward looking statements and information that are based upon beliefs of, and information currently available to, the company's management as well as estimates and assumptions made by the company's management. When used in this presentation the words "anticipate," "believe," "expect," "future," "intend," "plan" or the negative of these terms and similar expressions as they relate to the company or the company's management identify forward looking statements.

Such statements reflect the current view of the company with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the company's industry, its operations and results of operations and any businesses that may be acquired by the company. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

We caution that the foregoing list is not exhaustive of all possible factors, as other factors could adversely affect our results, performance or achievements. The reader is cautioned against undue reliance on these forward-looking statements. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, the company cannot guarantee future results, levels of activity, performance or achievements. The inclusion of such forward looking statements should not be regarded as a representation by the Company or any person that the future events, plan or expectations contemplated by the Company will be achieved. Except as required by applicable law, including the securities laws of the United States and Canada, the company does not intend and assumes no obligation to update or revise any of the forward-looking statements if new information becomes available, as a result of future or for any other reason to conform these statements to actual results.

CanaQuest MEDICAL CORP

Problem – Mental Disorders On The Rise

| Limited science behind “medical” cannabinoid products

- Global cost - mental disorders will cost the global economy $16 trillion by 2030[1]
- Mental health ailments - 1 in 5 North Americans has some type of mental health condition[2,3]
- Limited science-backed cannabinoid natural plant solutions - to treat mental Illnesses (alternative to opioids)
- Cannabinoid medicine - physicians have a difficult time prescribing precise doses
- Neurological treatment limitations – cannabidiol (CBD) by itself does not effectively cross the blood-brain barrier
- Only one CBD pharmaceutical drug on the market – approved by the US-FDA – to treat epileptic neurological conditions – Epidiolex®, developed by former GW Pharma

Cannabinoids without science is not medicine

1) Psychiatric Times, November 2018

2) Open Minds, May 13, 2020

3) Mental Health Commission of Canada

CanaQuest MEDICAL CORP

Solution - Game Changing Formulations

|Cannabinoid molecules used as formulation bases for Rx drug candidates



CQ-001 – cannabidiol (CBD) + IP formula

Drug candidate

- Molecules bond and synergistically attach to PPAR receptor allowing CQ-001 to cross the blood-brain barrier (BBB) to target the central nervous system (the brain) with amplified effects and efficacy. CBD by itself does not do this in the pre-clinical trials .

Pre-clinical trial results - published in peer-reviewed European Journal of Neuroscience. Oct. 2020.



CQ-002 – cannabinoid (THC) + IP formula

Drug candidate

- A *safer alternative* to all other THC products. Pre-clinical trials demonstrated reversal of depression-like and schizophrenia related symptoms, complete blockage of memory impairment, hyperactive activity, and gene vulnerability.

Pre-clinical trial results - published in peer-reviewed Journal of Neuroscience Dec. 2020 & International Journal of Molecular Sciences July 2021.

Note: International Patents filed

Value Proposition – Rx Drug Candidates for Pre-approved Trials

| Novel formulation bases, proprietary processing, and delivery formats for Rx drug candidates (1)

Western

CRCHUM CENTRE DE RECHERCHE
University of Montreal
Hospital Research Centre

McMaster University

The Epilepsy Research Program of the Ontario Brain Institute EPLINK
Ontario Brain Institute

- Pre-clinical trials completed – Western University
- Pre-approved and Pending Clinical Trials
  - University of Montreal (Phase II).....pre-approved and funded
  - McMaster University (Phase II).....pre-approved and funded
  - Ontario Brain Institute (Phase II/III)....clinical study funded & a pending clinical trial
- Regulatory pathways mapped out to obtain **Rx** Drug Identification Numbers (DINs) in the USA and Canada for Epilepsy rare neurological conditions, projected ~ 3 years

Note (1): Formulation bases for drug candidates to conduct clinical trials to treat:

⚕Anxiety & Depression ⚕ PTSD, Schizophrenia ⚕ Pain Management ⚕ Addiction ⚕ Other neurological conditions

The Scientific Difference

CBD



vs. CQ-001

Pure Cannabidiol

Scientifically developed proprietary formula

CBD……

- Does not effectively cross the blood-brain barrier “BBB“ to reach the section of the brain that regulates emotion. Thus, CBD alone is marginally effective for treating mental ailments.
- Has nominal effect on neurological conditions.
- Achieves minimal efficacy with digested high doses that cause negative side effects (especially toxicity of the liver).

CQ-001 – pre-clinical trials demonstrated……

- **New Pathway Discovery:** Molecules bond and synergistically attach to PPAR receptor allowing **CQ-001** to cross the BBB to target the central nervous system (the brain) with amplified effects and efficacy.
- Addresses neurological conditions such as epilepsy, including anxiety, depression, PTSD, schizophrenia and addiction.
- Requires minimum doses of CBD, yielding increased efficacy since **CQ-001** effectively crosses the BBB.

* Data derived from scientific research and pre-clinical trials by Dr. Steven Laviolette, Neuroscientist, Western University.

CanaQuest MEDICAL CORP

Pharmaceutical Comparable - Unique Formulation

| Comparison with similar FDA approved product

CQ-001   CanaQuest MEDICAL CORP	**Epidiolex®**  GW pharmaceuticals
Double acting formula – on the center nervous system (the brain) and endocannabinoid system	Acts on the endocannabinoid system, requiring high dosage to reach desired results at the brain level
• Active ingredients: CBD + IP formula • Molecules bond & synergistically cross the blood-brain barrier • Multible X more efficacy • Lower dose of CBD required	Formula: 99% CBD – sesame as carrier oil (non-active)
• Sublingual delivery (spray, under the tongue, buccal) - bypassing digestive system, eliminating liver toxicity • 80% to 90% of formula enters bloodstream • Onset within minutes	• Oral delivery - can lead to liver toxicity • Only 10% of the formula enters the blood stream • Effect in hours
Proprietary formulation, CQ-001 - Pricing TBD	Pure CBD, Epidiolex® Rx ~ US$1,500/100ml

The Scientific Difference

THC



Pure Cannabinoid

vs CQ-002

Scientifically developed proprietary formula

THC can cause……

- Memory impairment & possible long-term cognitive side effects
- Depression-like and schizophrenia-related symptoms
- Anxiety and hyperactive activity
- Schizophrenia due to gene vulnerability

CQ-002 (a safer alternative to THC) – pre-clinical trials demonstrated……

- Blockage of memory impairment
- Reduced depression-like and schizophrenia related symptoms such as paranoia, and in some cases, it reversed symptoms
- Blockage of hyperactive activity and anxiety
- Blockage of gene vulnerability related cognitive issues*

* Data derived from scientific research and pre-clinical trials by Dr. Steven Laviolette, Neuroscientist, Western University.

CanaQuest MEDICAL CORP

Mental Health Costs

| Significant Mental Health Ailments to be Addressed

$16 Trillion Mental Illness Will Cost the World $16 USD Trillion by 2030[1]

$225 Billion Mental Health Costs in the US reached $225 USD Billion in 2019 - 5.5% of all health spending[2]

$50 Billion Mental Illness in Canada is at least $50 Billion per year and growing substantially[3]

51.5 Million 20.6% (1 in 5) of U.S. adults experienced mental illness in 2019 (51.5 million people)[4].

1) Psychiatric Times, November 2018

2) Open Minds, May 13, 2020

3) Mental Health Commission of Canada

4) National Alliance on Mental Illness (NAMI)

Pharmaceutical Regulatory Pathway To Market - CQ-001

| Patients Suffering from Epilepsy – Dravet & Lennox-Gastaut Syndrome, and Tuberous Sclerosis Complex



Total Addressable Market ~ 1.1M patients worldwide

Serviceable Addressable Market 160,000 patients in US, Canada & EU

Serviceable Obtainable Market 80,000 patients (50%) in US, Canada & EU

Note: 1 – For illustrative purposes

Executive Team & Board of Directors

| 100+ Years of Management & Product Development Experience

Richard Rusiniak, Mechanical Engineer, CEO – Director

- Over 35 years of management, design and process experience;
- Co-founder and former President, CFO, and CTO of Cymat Corp (TSX: CYM) with a market valuation over $150 million;
- Former project manager with Long Manufacturing, as well as The Ontario Research Foundation (Ortech). Projects on which he has consulted include NASA's Zero Gravity Program, Atomic Energy of Canada's Re-tubing Program and Hawker Siddeley's Bi-Level GO Train Modularization.

Paul Ramsay, BBA, President – Chairman

- Over 30 years of business development and management experience;
- Co-founder and former CEO and VP Business Development of Cymat Corp, (TSX: CYM) with a market valuation over $150 million;
- Introduced and sold several newly developed products to several major corporations.

Ross Eastley, CA, CFO – Director

- Over 35 years of accounting and CFO experience in both private and public sector organizations;
- Former CEO for the Canadian Society of Immigration Consultants (CSIC);
- Former VP/Controller for Brandon University, Manitoba.

Cameron McDonald, BA, BSc, MBA – Independent Director

- Venture capital executive and entrepreneur with over 25 years of corporate finance and business development experience;
- Currently the CEO of Ocean Trout Canada Inc., a leading Canadian aquaculture company;
- Formerly an investment banker with Canaccord Adams (now Canaccord Genuity), worked on over $500M in public financings on TSXV and AIM exchanges as well as M&A advisory assignments, has completed the Chartered Financial Analyst "CFA" program.

CanaQuest MEDICAL CORP

Scientific Partners & Regulatory Advisors

Dr. Steven Laviolette, B.Sc., Ph.D., a Professor and Neuroscientist in the Schulich School of Medicine & Dentistry at Western University, Addiction Research Group Dept. of Anatomy & Cell Biology, Dept. of Psychiatry **R & D Program - 14 scientists**

https://www.laviolettelab.com/ For a short video on the research, visit https://www.youtube.com/watch?v=O_D4wkHHbDg

- Recipient of numerous national and international research awards;
- Dr. Laviolette's research team has made numerous discoveries related to how the mammalian brain is influenced by chronic drug exposure and how signaling through the brain's cannabinoid and opioid systems can control emotional processing in specific brain circuits;
- Research from Dr. Laviolette's team has been published in the top tier of neuroscience and psychiatry journals in the world.

Dr. Tom Ng, B.S., Ph.D., COO, BioPharma Global, **Regulatory Consultants - 7 Leadership Team Members**
https://www.biopharmaglobal.com/about-us/

- Dr. Ng's academic background includes a B.S. in Biochemistry from the **University of Maryland** and a Ph.D. in Molecular Biology from **Johns Hopkins University**. He is also an Executive Board Member and President Emeritus of the CMNS Alumni Association Chapter at the University of Maryland;
- BioPharma Global is a full-service regulatory affairs consulting firm specializing in orphan products to treat rare diseases and non-orphan products;
- The team is comprised of globally recognized experts in rare diseases and other under-served disease areas, **including former FDA staff.**

Veterinarian & Scientific Partners

| Pre-approved program & Government Grant, MITACS
– anxiety & pain, Veterinary Drug Candidates based on CQ-001 & CQ-002

Dr. David W.L. Ma, Ph.D. Medical Sciences, Professor, Department of Human Health and Nutritional Sciences, University of Guelph
R & D Program - 5 scientists https://www.uoguelph.ca/hhns/people/dr-david-wl-ma

- Previously, had faculty position in the Department of Nutritional Sciences at the **University of Toronto**;
- Pursued postdoctoral training examining the linkage between diet and cancer at **Texas A&M University** studying the role of omega-3 fatty acids and folate in colon cancer;
- To date, Dr. Ma has authored over 130 peer reviewed publications.

Dr. Adronie Verbrugghe, Ph.D., Associate Professor, Veterinary College, University of Guelph
https://ovc.uoguelph.ca/clinical-studies/faculty/Adronie-Verbrugghe

- Graduated as a companion animal veterinarian (DVM) from **Ghent University, Belgium** in 2005, completed her PhD focusing on nutritional modulation of carbohydrate metabolism in cats in 2009 and 2 additional years as a postdoctoral fellow;
- Became board certified for the **European College of Veterinary and Comparative Nutrition** in 2010. In 2011, Dr. Verbrugghe joined the Ontario Veterinary College (OVC), **University of Guelph**, as Royal Canin Veterinary Diets Endowed Chair in Canine and Feline Clinical Nutrition;
- To date, Dr. Verbrugghe has authored 35 peer-reviewed publications.

Medical Advisory Board

| Physicians, Psychiatrists & Healthcare Practitioners – being built

Remi A Menes, BSc, MBA, Chairman of the CanaQuest, Advisory Committees

- Extensive commercial, operations and business development experience in the biopharmaceutical, biotech, pharmaceutical, and cannabinoid sector.
- Experience with launching pharmaceutical products; developing product life-cycle management strategies; establishing head office, division and field capabilities - in Canada, USA, Japan, Latin America and Western Europe.

Advisor Expertise and Shared Values:

- Scientific knowledge and expertise in cannabinoid-based medicine
- Currently or amenable to prescribing cannabinoids
- MD Advisors recommended by Strategic Investment Partner (TBD).

Nutraceutical Division
Partnerships – Manufacturing

| Two commercial ready Master Formulations
Near term revenue

Canada

Launching: Q3 2022

Mentanine® (CBD + IP formula) - powder

Mentabinol® (THC + IP formula) - powder

Hydrx Farms, Ontario https://hydrx.ca/facilities/

- GMP compliance with regulatory requirements of Health Canada
- Constructed as a pharmaceutical & research facility
- Producing SOPs for Mentanine® and Mentabinol® (water soluble, high bioavailability).

USA

Mentanine® launched: June 2022

ATRIUM

Atrium Scientific, California www.atriumsci.com

- GMP Processor, class-1000 clean room and lab
- Supply chain process – from cultivation to distribution
- Producing Mentanine® (water soluble, high bioavailability) – May 2022.

CanaQuest MEDICAL CORP

CanaQuest Highlights

| World-leading scientists in neurology, clinical trials and Rx Drug Approvals

- Leader - in cannabinoid-based drug development for treating mental health neurological conditions
- Clinical trial stage - strong science, pre-clinical trial results and peer-reviewed reputable publications for drug candidates, CQ-001 & CQ-002
- Game changers – CQ-001 synergistically attaches to PPAR receptor allowing CBD to cross the blood-brain barrier (BBB) to interact with the central nervous system (the brain) for amplified effects & CQ-002 - a *safer alternative* to all other THC products
- Clinical trials - Drug Candidates CQ-001 & CQ-002, University of Montreal Phase II, McMaster University Phase II, and Ontario Brain Institute Phase II/III
- Comparable - pre-clinical trials demonstrated greater efficacy and fewer side effects than Epidiolex®
- Regulatory pathways - mapped out to obtain **Rx** Drug approvals for Epilepsy rare diseases, ~ 3 years
- Exit via acquisition - GW Pharma acquired by Jazz Pharma for $7.2 B, 2.5 years after launching Epidiolex®

Winner of the 2021 *Best Medical Cannabis and Botanical Oils Product Development Company – North America*, awarded by Global Health & Pharma, UK

Winner of the *International CBD Life Science R&D Excellence Award 2020*, given by Global Health & Pharma, UK

CanaQuest MEDICAL CORP

Thank you

Contact Information:

Paul Ramsay, President

416.704.3040

paul@canaquest.com

www.canaquest.com

Steps to US-FDA and Heath Canada Approvals

Obtaining Drug Identification Numbers DIN for Rx CQ-001

Targeting Rx drug candidate for two epilepsy rare conditions

COMPLETED STEPS

- ✓ **CanaQuest Scientific Partnership Network**
  - ✓ Completed pre-clinical trials
  - ✓ Pre-approved clinical trial programs
- ✓ **Eurofins**: active service provider to obtain Health Canada approvals
- ✓ **Biopharma Global**: Full Service Agreement in place for US-FDA approvals
- ✓ **Hydrx Farms:** GMP pharmaceutical compliance manufacturer. Completing SOPs.

NEXT STEPS TO OBTAIN A DIN FOR CQ-001 – CBD molecules + formula

US-FDA

Work with BioPharma Global and Partners to follow through with:

- Clinical trial (Phase II/III) for epilepsy, Ontario Brain Institute
- Orphan Drug Status designation for expedited regulatory review of CQ-001
- Priority Review Voucher (PRV) which can be sold (extra PRV issued for orphan drugs of rare diseases afflicting < 200k patients and for children)
- Application for Breakthrough Therapy Designation and NDA New Drug Application submitted after clinical trials => US-FDA DIN approval projected ~ 3 years

Health Canada

Work with Eurofins and Partners to obtain:

- Priority Review Status - achieved once Orphan Drug Status is issued in the USA and if there is no comparable approved Rx drug in Canada
- Priority Review Status is needed for Health Canada's approval of CQ-001 as a pharmaceutical drug, issuing a conditional DIN under the term Notice of Compliance with Conditions (NOC/c)
- Unconditional Health Canada DIN projected ~ 2 years

Steps to US-FDA and Heath Canada Approvals

| Obtaining Drug Identification Numbers DIN for Rx CQ-002

Targeting Rx candidate as a neurological drug



COMPLETED STEPS FOR Rx CQ-002

- ✓ **CanaQuest Scientific Partnership Network**
  - ✓ Research and pre-clinical trials completed
  - ✓ Ready for establishing clinical trials
- ✓ **Eurofins & Biopharma Global**: active service providers to obtain Health Canada & US-FDA approvals
- ✓ **Hydrx Farms:** GMP pharmaceutical compliance manufacturer. Completing SOPs.

NEXT STEPS TO OBTAIN A DIN FOR CQ-002 – THC molecules + formula

Work with Eurofins and Partners to follow through with:

- Clinical trial (Phase II) for efficacy and dosage, CQ-001 & CQ-002 separately and combined, University of Montreal

Work with Eurofins and BioPharma Global to:

- Review CanaQuest's regulatory strategy and identify gaps
- Advise on regulatory pathway for CQ-002
- Submit clinical trial applications, working in conjunction with the scientists and regulators.
- Advise on regulatory process and issues with the US-FDA

Projected ~ 2.5 years for Health Canada approval following the Clinical Trials Application (CTA) - building on vast pre-existing data on THC cannabinoids.